Additional information
| Strength | 10mg, 2mg |
|---|
$250.00
Classified as a senolytic research peptide
FOXO4-DRI is a peptide designed to selectively disrupt FOXO4-p53 interactions in senescent cells, enabling apoptosis and clearance of senescent cell populations in preclinical models
For research use only. Not for human or animal consumption.
Not evaluated by FDA. Not intended to diagnose, treat, cure, or prevent disease
Reviews
There are no reviews yet.